Coiled Therapeutics (AIM:COIL), the AIM-listed clinical-stage oncology company, will present the latest data on its lead drug candidate at the 18th Annual World Cancer Congress in Athens this week.
Executive chairman Sotirios Stergiopoulos will speak on 16 April on AO-252, a first-in-class TACC3 inhibitor being developed for hard-to-treat cancers, including brain metastases.
The presentation follows a recent clinical trial update showing superior efficacy and durable responses in heavily pre-treated patients.